Recently,theglobalHealthcareIndustryhasbeen proliferating.Thisgrowthisprimarilydrivenby bothpublicaswellasprivatesectorsincreasing expenditureontheoverallhealthofthemiddleeastern communitiesspreadoveravastgeographicalarea. Similarly,theongoingpandemichasbeenaccelerating awarenessatanunprecedentedrateintheregion.
Also,withpeople’sopeningmindsetofembracing advancedtechnologiesenteringthehealthcaresector,many globalhealthcarecorporationsareshowingakeeninterest infurtherinvestinginthehealthcareindustry.Notonly them,butmanylocalplayersareputtingintheirefforts, moneyandtimetotransformthefaceofthewellnesssector.
Allinall,theindustryhasalreadyrevampeditselftomeet thepresentandfutureuncertaintiesandchallengeshead-on. Atthehelmofthistransformationisanewgenerationof stalwartswhoareshoulderingthistremendous responsibilityofcarryingoutasocio-transcendental missionofenhancingthequalityofeveryone’shealthand wellnessandextendingthepopulation’soveralllifespan.
Thesestalwartscouldbecalledvisionaries,astheyarenot onlypassionateaboutthissocialmissionofspreading equality,happiness,care,compassion,health,andqualityof lifeawarenessbutalsoincludemoreandmorepeopleintoit byusingeverypossibletoolandtechniqueintheirpower.
Today,itisbecauseoftheseexemplarypersonalitiesthat wecouldseethe‘FirstandSecondGlobalHealthcare MetaversePlatform,’PaperlessMedicationinitiative,novel healthmonitoringandsurveillancetechcomingin,opening upofnewhealthcareandmedicinalR&Dlabsforlocal healthcareresearch,production,anddelivery,explorationof
bio-convergence,useofadvancedsoftwaretechnologies, andmobileappstoprovidein-clinicandremoteaswellas telehealthtothewidespreadpopulation.
Inanattempttograsptheexactscopeofthis transformation,InsightsSuccesscarriedoutitsown researchandfoundthe‘The Top 10 Pharmaceutical Companies to Watch in 2023,’anddepictedtheir revolutionarytalesinthefollowingpagesalongwithtwo trendyarticleswrittenbyourin-houseeditorialteam,so thatyoucouldhaveathoroughcomprehensionofthese leaders’monumentalaccomplishments.
Flipthroughtheeditionandexplore‘ANewFutureofthe Pharmaceuticalsandtheever-evolvingHealthcaresector.’
O N T E N T S
Deputy
Marketing
Business
sales@insightssuccess.com
April, 2023
Actylisisaleadingmanufacturerandsupplierofcriticalraw materialsandperformanceingredientsservingtheLife Sciences,SpecialtyChemicals,andAgriscienceindustries.
Adaptimmuneisaclinical-stagebiopharmaceuticalcompany focusedonthedevelopmentofnovelcancerimmunotherapy productsforcancerpatients.
AngeliniPharmaisaleaderinhealthcare,withparticular strengthandexpertiseinthefieldsofMentalHealthand Epilepsy.
Anikaisaglobaljointpreservationcompanycommittedto deliveringmeaningfuladvancementsinearlyintervention orthopediccare.
Merzstrivestoprovidemoregooddaystoeverypatientby investigatingnovelandflexibleneurotoxintreatmentoptions.
NeuraxpharmisaleadingEuropeanspecialtypharmaceutical companyfocusedonthetreatmentofcentralnervoussystem (CNS)disorders.
NordicPharmaisaninternationalmarketingandsales companywithahistoryofinternalproductdevelopmentand acquisitions.
OysterPointPharmaisabiopharmaceuticalcompanyfocused onthediscovery,developmentandcommercializationof therapiestoaddressophthalmicdisease.
RigelPharmaceuticalsisabiotechnologycompanydedicatedto discovering,developingandprovidingnoveltherapiesthat significantlyimprovethelivesofpatients.
UroGenPharma isabiotechcompanydedicatedtodeveloping andcommercializinginnovativesolutionstotreaturothelialand specialitycancers.
GearoidO'Rourke VPofGlobalMarketing Actylis actylis.com DanaLynch SeniorDirectorof CorporateCommunications Adaptimmune adaptimmune.com DanielaPoggio GlobalCommunications ExecutiveDirector AngeliniPharma angelinipharma.com MarkNamaroff CorporateCommunications Anika Therapeutics,Inc. anika.com KarolinaDzeko-Balke CorporateCommunications MerzTherapeutics merz.com AnnaVidalLlanos CommunicationsManager Neuraxpharm neuraxpharm.com PascalePoulain-Arnaud GlobalMarketingDirector NordicPharma nordicpharma.com KarenCastillo-Paff MediaRelations OysterPointPharma oysterpointrx.com DavidRosen MediaRelations Rigel PharmaceuticalsInc. rigel.com CindyRomano DirectorCorporate Communications UroGenPharma urogen.comActyliswascreatedtounitea widerangeofcapabilitiesinto anew,globalenterprisewitha uniquehybridapproachthatis greaterthanthesumofitsparts.
Qualityrawmaterialsarethebackboneofany industry,especiallyLifeSciences,whererobust manufacturingprocesses,exceptionalquality controlandregulatorycompliancearedemandedfrom suppliers.
Actylisisaleadingmanufacturerandsupplierofcritical rawmaterialsandperformanceingredientsservingtheLife Scienceindustry.Itoffersstandardandcustomingredients throughitsrapidlygrowingportfolioofGMPandnon-GMP facilitiesworldwideandfurtherchoicethroughitsstrong sourcinghubnetwork.Itgivesauniquehybridoption blendingmanufacturingandglobalsourcing,combined withmorethan75yearsofindustryexperience.Itstagline reads‘PartnerofChoice,’showcasingacommitmenttobea partner,ratherthanasupplier,toitsclients.
Actylisistheresultoftheamalgamationofelevendifferent companies(A&C,A&CBioBuffer,Aceto,Biotron Laboratories,CascadeChemistry,Finar,InterActifs, IsleChem,PharmaWaldhof,SyntorFineChemicals,and Talus),eachwithkeynicheandmainstreamstrengths. Manyofthesecompanieswereacquiredbetween2019and early2022,andtheActylisbrandwasbornattheendof Septemberof2022.Internalandcustomerresearchrevealed thathaving11separatebrandswasnolongersustainable. Instead,asingle,unifiedbrandwasneededtoshowcaseits hybridapproach.
Actylishasgrownfrom200peopletoover850inten countriesacrossthreecontinents. Salesareover$600+ millionperyear,andithasmanufacturingandR&D facilitiesacrosstheglobe. Thisbusinessgrowthhasbeenin parallelwithdiversificationgrowth–improvingthegender andrace,balanceacrossalllevelsofsenioritywithinthe organisation.
InanexclusiveinterviewwithInsightsSuccess,Gearoid O’Rourke,VPofGlobalMarketing,sharesActylis’birth,its edgeinthemoderncompetitivelandscape,andhowitplans todeliveronitsdevelopmentplans.
Belowarethehighlightsoftheinterview:
WhatwastheinitialideabehindthecreationofActylis?
Actyliswascreatedtouniteawiderangeofcapabilitiesof severalmanufacturingandsourcingspecialistsforthelife scienceindustryintoanew,globalenterprisewithaunique hybridapproachthatisgreaterthanthesumofitsparts.
Thesynergiesthatexistbetweentheindividualcompanies (A&C,A&CBioBuffer,Aceto,BiotronLaboratories, CascadeChemistry,Finar,Inter-Actifs,IsleChem,Pharma Waldhof,SyntorFineChemicals,andTalus)haveallowed ustocreateacompanythatprovideskeybenefitstoour customersinhigh-growthendmarkets,including Biopharma,pharma,cosmetics,nutrition,andspecialty chemicals.
Actylisbringstogetherourcombinedbroadcompetencies, intimateknowledgeofcustomers’needs,consultative perspective,andfocusoninnovationandqualitytoprovide unparalleledchoiceandflexibilitytoourcustomers.
Whataretheprimaryobjectivesandphilosophyof Actylis?
Actylisistheculminationofanambitiousinitiative launchedseveralyearsagotoaddressthemajorunmetneed forbetterandmoredependableaccesstocriticalraw materialsandperformanceingredientsessentialforthe manufactureofhighlyregulatedproductsinkeyindustries. Thesupplychainchallengesofthepastfewyearshave madeourvisionforActylisespeciallyrelevant,andweare proudtohelpourcustomersdependablymanufacturethe life-givingproductsweallrelyon.
Whatproduct/serviceofferingssetyouapartfromyour competitors?
Withover75yearsofmanufacturingandsourcing experienceandaportfolioofGMPandnon-GMP manufacturingfacilitiesacrossmultipleregions,weoffer customerstheflexibilitytochoosefromawideproduct portfolioandcustomizedsolutions,allbackedbythesame world-classquality,supplychainreliability,andregulatory expertise.OurcapabilitiesincludeglobalR&Dcentersof excellence,GMPandNon-GMPmanufacturingplantsin variouslocationsinNorthAmerica,Europe,andAsia, sourcinghubsatstrategiclocations,aswellasglobalsupply chain,technicalsalesandqualityteamsinover10 countries.
Whatdoyouseeasthekeyshorttermchallengesfacing yourindustry?
Companieslikeusmustbeabletomovequicklytoadjust tothechallengesofthelifescienceindustry.Wehavebuilt ourstrategyaroundagilityandflexibilitytomanagethe developingareasthatourindustryface:
Ÿ Amovetowardsmorelocalsupplytomitigaterisk.
Ÿ Areversalofrawmaterialsupplierconsolidationto friend-shoringandsupplydiversity.
Ÿ Anevengreaterfocusonsustainability.
Ÿ Areductionoffocusonleanmodels,replacedby smarterinventoryplanningapproachesandsupplier diversity
HowisActylisadaptingtotheever-changingdemands ofyourcustomers?
Actylis’businessstrategywasbornoutofthecurrent markettrendsintheLifeSciencesector–theneedformore flexibilityandagilityinrawmaterialmanufacturingand supply
Asourindustryevolvesandmanufacturingprocesses develop,weconstantlyreviewglobalandlocal technologicaladvancesandlegislative®ulatory
Ourstrategyissimple–provideourcustomers withchoice.Wewill continuetomaturethis strategyviaorganicgrowth andmoreacquisitionsin thelifesciencesectorin thefuture.TheTop10PharmaceuticalCompaniestoWatchin2023
changestoensureweareatthecuttingedge.Asan example,wehaverolledoutaglobaleQMS (MasterControl)toensurewearealloperatingonthe unifiedsystemtogiveourcustomersassuranceofour globalqualitymanagementregardlessoflocation.
Howdoyoudealwiththeconstantinnovation challengesfromyourcustomer?
Theindustryweserveisagloballeaderininnovative technologyadoption,suchastargetedtherapiesandgene andcelltherapies.Asarawmaterialsupplier,wealsoneed tobeflexibleandagiletocreatecustomizedcriticalraw materialstoservethisinnovativemarket.OurR&DCenters ofExcellenceworkcloselywithourcustomerstodevelop novelandnicheingredientstoenableourcustomersmore rapidlycommercializetheirfinisheddrugproducts.
HowisActylisdealingwithitsenvironmental,socialand localcommunityresponsibilities?
Fortheglobalcommunity,wehaverecentlylaunchedour corporatesustainabilitystrategy,focusingonthreekey areas–ensuringenvironmentalandsocialstandardsinour supplychain,monitoringourcarbonemissionsand reducingourclimateimpact,andcaringforthe environmentalfootprintofourproducts.Youcanfindout moreinformationaboutoursustainabilityjourneyonour website.
Fromalocalperspective,wesupportcommunityinitiatives inmanyofthelocalitiesthatwehavefacilitiesinand supportmanylocalandinternationalinitiativesand charities.
Ourstrategyissimple–provideourcustomerswitha choice.Wewillcontinuetomaturethisstrategyviaorganic growthandmoreacquisitionsinthelifesciencesectorover thecomingyears.
Be er Health and a better way of life.
Thefieldofpharmaceuticalresearchhasexperiencedremarkable
advancementsovertheyears,primarilydrivenbytheintegrationof cutting-edgetechnologies.Thesetechnologicalinnovationshave transformedeveryaspectofdrugdiscoveryanddevelopment,fromtarget identificationandvalidationtoclinicaltrialsandpost-marketsurveillance. Thisarticleexploresthepivotalrolethattechnologyplaysinenhancing pharmaceuticalresearch,revolutionizingthewayscientistsapproachdrug discovery,safetyassessment,andpatientcare.
Oneofthemostsignificantcontributionsoftechnologytopharmaceutical researchistheintroductionofhigh-throughputscreening(HTS)and computationalmodeling.HTSenablesresearcherstorapidlytestthousands ofpotentialdrugcompoundsagainstatarget,expeditingtheidentification ofleadcompoundswiththerapeuticpotential.Coupledwithcomputational modelingtechniques,suchasmoleculardockingandquantitativestructureactivityrelationship(QSAR)analysis,scientistscanpredicthowdifferent compoundswillinteractwithbiologicaltargets.Thisacceleratesthedrug discoveryprocessbyreducingthetimeandresourcesrequiredforhit identificationandleadoptimization.
Omicstechnologies,includinggenomics,proteomics,andmetabolomics, haverevolutionizedourunderstandingofdiseasemechanismsand individualpatientvariability Thesetechnologiesenableresearchersto analyzelarge-scalemoleculardatatoidentifybiomarkers,drugtargets,and potentialadverseeffects.Personalizedmedicinehasemergedasaresult, tailoringtreatmentstoapatient'suniquegeneticmakeupanddisease profile.Advancesinbioinformaticsanddataanalyticsfurthersupportthe interpretationofcomplexomicsdata,facilitatingthedevelopmentofmore effectiveandtargetedtherapies.
Artificialintelligence(AI)andmachinelearning(ML)have emergedasgame-changersinpharmaceuticalresearch. Thesetechnologiesanalyzevastdatasets,extracting meaningfulpatternsandinsightsthathumansmight overlook.AI-poweredalgorithmscanpredictdrug-drug interactions,assessthelikelihoodofsideeffects,and optimizeclinicaltrialdesigns.Indrugdiscovery,AI-driven virtualscreeningidentifiespotentialdrugcandidatesby simulatingmolecularinteractions.Additionally,machine learningmodelsaidinpredictivetoxicology,helpingto identifycompoundswithpotentialsafetyconcernsearlyin thedrugdevelopmentprocess.
Technologyhasreshapedhowclinicaltrialsareconducted andhowpatientdataiscollected. Wearabledevices,mobileapps,andelectronichealth recordsallowforreal-timemonitoringofpatients,enabling researcherstogathercontinuous,objectivedata.Thisrealworldevidenceprovidesvaluableinsightsintoadrug's efficacyandsafetyindiversepatientpopulations, potentiallyleadingtomoreefficientclinicaltrialdesigns andfasterregulatoryapprovals.
Nanotechnologyhasunlockedinnovativeapproachesto drugdelivery,enhancingtheeffectivenessandspecificityof therapeuticinterventions.Nanoparticlescancarrydrugsto specificsiteswithinthebody,improvingdrug bioavailabilityandminimizingsideeffects.Moreover, nanotechnologyenablesthedevelopmentoftargeted therapies,wheredrugsarereleasedonlyattheintendedsite ofaction,maximizingtherapeuticbenefitandreducing systemictoxicity
Virtualrealityandaugmentedrealitytechnologieshave foundapplicationsinpharmaceuticalresearch,particularly indrugdesignandmedicaltraining.Indrugdiscovery, scientistscanuseVRtovisualizeandmanipulatecomplex molecularstructuresinthreedimensions,aidinginthe designofnovelcompounds.ARcanenhancemedical trainingbyprovidingimmersivesimulationsofsurgical procedures,allowingmedicalprofessionalstopracticeand refinetheirskillsinarisk-freeenvironment.
TherevolutionaryCRISPR-Cas9geneeditingtechnology hasopenedupnewavenuesforpharmaceuticalresearch. Scientistscannowpreciselyeditgenestostudydisease mechanisms,validatedrugtargets,andevendevelopgene therapies.CRISPR-Cas9hasthepotentialtocorrectgenetic mutationsresponsibleforvariousdiseases,offeringhope forpreviouslyuntreatableconditions.
Advancementsin3Dbioprintingtechnologyenablethe creationofcomplextissuestructuresandevenfunctional organsinthelaboratory Thesebioprintedtissuesand organsprovidevaluableplatformsfortestingdrugefficacy andtoxicity,reducingtherelianceonanimalmodelsand enhancingthepredictabilityofpreclinicalstudies.Organon-a-chipmodelssimulatethefunctionsofhumanorgans, offeringamoreaccuraterepresentationofphysiological responsestodrugsandenablingpersonalizedmedicine approaches.
Thepharmaceuticalindustrydealswithmassiveamountsof sensitivepatientdata,researchfindings,andclinicaltrial information.Blockchaintechnologyprovidesasecureand transparentwaytomanageandsharedata,ensuringdata integrity,traceability,andconfidentiality.Byimplementing blockchainsolutions,pharmaceuticalcompaniescan streamlinedataexchangeamongstakeholders,reducedata tamperingrisks,andenhancecollaborationinmulti-center clinicaltrials.
Roboticsandautomationhavetransformedlaboratory workflows,makingexperimentsmoreefficient, reproducible,andhighthroughput.Automatedliquid handlingsystems,roboticassays,andlaboratoryrobotscan performrepetitivetaskswithprecision,reducinghuman errorandfreeingresearcherstofocusonmorecomplex aspectsofdrugdiscovery.Thistechnologyacceleratesthe screeningofcompoundlibraries,optimizingdrug candidatesforfurtherdevelopment.
Thehealthcaresectorisundergoingaprofoundtransformation,
drivenbyrapidtechnologicaladvancements,shifting demographics,evolvingpatientexpectations,andthe increasingimportanceofpreventiveandpersonalizedmedicine.Aswe ventureintoaneweraofhealthcaredelivery,understandingthe emergingtrendsinthemodernhealthcaresectoriscrucialfor healthcareprofessionals,policymakers,andpatientsalike.Thisarticle delvesintosomeofthemostsignificanttrendsshapingthefutureof healthcare.
Theproliferationoftelehealthandremotepatientmonitoring technologieshasrevolutionizedhealthcareaccessibility.Patientscan nowreceivemedicalconsultations,monitorchronicconditions,and accesspreventivecarefromthecomfortoftheirhomes.Thistrendhas becomeespeciallypertinentinlightoftheCOVID-19pandemic,where virtualcarehasplayedapivotalroleinmaintaininghealthcareservices whileminimizingphysicalcontact.
AIandmachinelearningarereshapinghealthcarediagnosis,treatment, anddrugdiscovery.Frompredictiveanalyticsthataidinidentifying diseaseoutbreakstoAI-drivenalgorithmsthatanalyzemedicalimages forearlydetectionofconditionslikecancer,thesetechnologiesare enhancingclinicaldecision-makingandpatientoutcomes.
Precisionmedicinetailorsmedicaltreatmentandinterventionsto individualcharacteristics,suchasgenetics,lifestyle,andenvironmental factors.Bytakingapersonalizedapproachtohealthcare,providerscan optimizetreatmentplans,reduceadversereactions,andimprove patientsatisfaction.
Wearabledevices,includingsmartwatches,fitnesstrackers,and biosensors,areempoweringindividualstomonitortheirhealthinreal time.Thesedevicescantrackvitalsigns,physicalactivity,sleep patterns,andmore,enablingpatientsandhealthcareprofessionalsto collaborateinmanaginghealthconditionsproactively
Blockchaintechnologyisenhancingdatasecurityandinteroperability inhealthcare.Itenablessecuresharingofelectronichealthrecords, ensuresdataintegrity,andenhancespatientprivacy,thusfosteringtrust amongstakeholdersinthehealthcareecosystem.
Healthcarereimbursementmodelsareshiftingfromfee-forservicetovalue-basedcare,whichfocusesonpatient outcomesandoverallhealthimprovement.Thisapproach incentivizeshealthcareproviderstodeliverhigh-quality, cost-effectivecareandemphasizespreventivemeasuresto reducetheburdenofchronicdiseases.
ARandVRtechnologiesarerevolutionizingmedical educationandtraining.Medicalstudentsandprofessionals cannowpracticesurgeries,simulations,andanatomical visualizationsinimmersivevirtualenvironments, enhancingtheirskillsandknowledgebeforeinteracting withrealpatients.
Theabundanceofhealthdatageneratedfromelectronic healthrecords,wearabledevices,andothersourcespresents anopportunityfordataanalyticstoinformclinicaldecisionmakingandpublichealthstrategies.Advancedanalyticscan identifytrends,predictdiseaseoutbreaks,andoptimize resourceallocation.
Modernhealthcareisincreasinglyshiftingitsfocustowards patient-centriccaremodels,emphasizingpatient engagement,shareddecision-making,andimprovedpatient experiences.Empoweringpatientswithinformationand involvingthemintheircarejourneyleadstobetterhealth outcomesandgreatersatisfaction.
Advancesingenomicmedicinehaveunlockedinsightsinto thegeneticbasisofvariousdiseases.Techniqueslike CRISPR-Cas9enableprecisegeneediting,offering potentialtreatmentsforgeneticdisorders.Genetherapies arebeingdevelopedtoaddressconditionsthatwereonce considereduntreatable.
Recognitionoftheimpactofsocialandeconomicfactors onhealthoutcomesisgrowing.Healthcareprovidersare
acknowledgingtheimportanceofaddressingsocial determinantssuchashousing,education,andaccessto healthyfoodtoimproveoverallpopulationhealth.
Roboticsarebeingintegratedintosurgicalprocedures, enhancingprecisionandallowingforminimallyinvasive surgeries.Surgeonscanremotelycontrolrobotic instrumentswithhighprecision,reducingrecoverytimes andcomplications.
Nanotechnologyoffersinnovativewaystodiagnose,treat, andpreventdiseasesatthemolecularlevel.Nanoparticles canbedesignedtotargetspecificcellsortissues,enabling moretargeteddrugdeliveryandimagingtechniques.
MobileHealth(mHealth)Apps:
Theproliferationofmobilehealthapplicationshas empoweredindividualstotakecontroloftheirhealth throughpersonalizedappsthattrackfitness,nutrition, medicationadherence,andevenprovidevirtualtherapy services.
HealthcareIoT(InternetofThings):
TheInternetofThingsisbeingleveragedinhealthcareto connectmedicaldevicesandequipment,allowingforrealtimemonitoringanddatacollection.Thisenhancespatient carebyprovidingaccurate,timelyinformationtohealthcare providers.
3Dprintingtechnologyistransformingthecreationof medicaldevices,implants,andevenorgans.Customized implantscanbeproducedquicklyandefficiently,leadingto improvedpatientoutcomes.
Theintegrationofbioinformaticsandbigdataanalysisis enablingresearcherstogaininsightsfrommassivedatasets. Thisapproachisacceleratingdrugdiscovery,disease understanding,andpredictivemodeling.
